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Abstract
We developed a 64 channel sensory electrical stimulator which delivers a dynamic and variable ‘Sensory Barrage’
Stimulation (SBS). Our aim was to assess the feasibility of caregivers delivering the stimulation in the community
for a clinical trial comparing single channel Transcutaneous Electrical Nerve Stimulation (TENS) with SBS for post
stroke upper limb spasticity. We trained caregivers of 16 participants with post stroke upper limb spasticity to
sequentially administer SBS and TENS for 60 min daily for four weeks each, with a washout period of two weeks
in between. Outcome measures tested were recruitment and retention rates, compliance with interventions and daily
recording of Participant -reported Numerical Rating Scale (NRS). We also collected results of Action Research Arm
Test (ARAT), Leeds Arm Spasticity Impact Scale (LASIS) and Modified Ashworth Scale (MAS) for spasticity. Out
of 21 potential participants, 16 consented and 15 completed the protocol. Ten participants received TENS for 80%
(23/28) of the intended hours. Eleven participants completed NRS for at 80% (45/56) of the study days. All
participants attended all visits. The MAS reduced by at least one in five participants after SBS and in three after
TENS. Minimal Clinically Important Difference (MCID) of four points increase in ARAT was seen in five partic-
ipants following TENS, and in four following SBS. A MCID of 18% decrease in NRS was reported by eight
participants after TENS and three after SBS. This study demonstrated the feasibility of undertaking a trial of sensory
electrical stimulation for post-stroke spasticity with caregivers delivering intervention in community. The study was
not powered to detect efficacy of the interventions. Trial registration number: NCT02907775.Date 20-9-2016.
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Spasticity is frequent sequelae of stroke and is associated with
increased utilization of health care resources.[1, 2] Caregivers
of stroke survivors with spasticity are more likely to experi-
ence anxiety and depression [3]. Spasticity is a significant
impedance for recovery of arm function following stroke
[4]. One in four stroke survivors develop spasticity within
the first 2 weeks of the stroke and by 12 months 39% experi-
ence spasticity [5, 6]. Oral antispasticity drugs often result in
side effects including sedation, weakness and floppiness [7,
8]. Compliance with oral antispasticity drugs among patients
with spasticity following a stroke is only around 50% [9].
Only a few exploratory studies on sensory stimulation
using Transcutaneous Electrical Nerve Stimulation (TENS)
for spasticity exist [10–13]. A Cochrane review in 2013 did
not find evidence at present to support its routine use [14]. A
recent systematic review and meta-analysis published in 2018
was also inconclusive due to the limited number of studies
[15]. TENS is a single-or dual channel, single strength and
fixed duration stimulation to which the nervous system may
get habituated, meaning that muscle responsiveness to the
treatment may lessen [16].
As part of a previous National Institute for Health Research
(NIHR)-funded project the Sheffield Teaching Hospitals team
had developed ‘ShefStim’ ; a unique miniaturised
(130x65x25mm) 64-channel programmable electrical stimu-
lator for treating drop foot. For this upper limb study, the team
re-engineered it to deliver novel sensory stimulation
(ShefStim-SBS) and achieved a further 40% reduction in its
size: to 150x58x15mm (Fig. 1). Unlike conventional stimula-
tors, ShefStim-SBS enables the intensity and timing of the
stimulation from each of the 64 electrodes to be controlled
independently. The electrodes were arranged to form an 8 by
8 array and with this configuration ShefStim-SBS was able to
programmatically control both the spatial and temporal char-
acteristics of the stimulation. The original ShefStim stimulator
was trialed for use as an orthotic aid to walking for people with
stroke and multiple sclerosis [17, 18]. During the course of
this upper limb project using the new ShefStim-SBS, we
pioneered the SBS technique of rapid simultaneous stimula-
tion at multiple sites, in a constantly changing pseudo-random
pattern. Non-impaired volunteers described it as a novel, in-
tense and tolerable sensation. This technique allowed us to
stimulate a wider area of the body and to vary the timing
and strength of each stimulus pulse in a random way
employing its 64 independent channels compared to the
single-site constant stimulation with standard TENS. As the
stimulation provides a larger area of continously changing
sensory input, we have termed it Sensory Barrage
Stimulation (SBS). We hypothesise that this approach will
significantly reduce habituation compared to single site stim-
ulation, thus providing a logical expansion of the paired asso-
ciative stimulation approach described by Ridding and Uy
[19]
As a precursor to this current study, we had conducted a
hospital-based double blind randomized crossover explorato-
ry trial comparing SBS with TENS for the treatment of spas-
ticity affecting the elbow flexor muscles [20]. Immediately
after a single 60 min session, both TENS and SBS groups
showed a reduction in spasticity. 70% participants continued
to respond (i.e. reduced spasticity) at 60 min after SBS, this
reduced to 40% continuing to respond at 60 min after TENS.
All participants tolerated both interventions well and none had
any significant adverse effects. A potential barrier for use of
electrical stimulation in treatment of spasticity is difficulty in
providing the treatment at home. The aim of this study was to
assess the feasibility of a clinical trial with caregivers deliver-
ing SBS and TENS in the domiciliary setting, for the treatment
of post stroke spasticity affecting the elbow flexors.
2 Materials and Methods
The protocol for this study was approved by the Yorkshire and
Humber Research Ethics Committee- Sheffield (IRAS project
ID: 202450). This trial was registered with the ClinicalTrials.
gov (NCT02907775).
The trial was a single blind randomized crossover trial; the
assessor was blind to the intervention. The investigator deliv-
ering the intervention was not involved in the assessment of
outcomes. The data analysis was done by an investigator who
was not involved in delivering interventions or assessing
outcomes.




Participants were identified from the hospital clinics and
community stroke services. When a potential participant
with post stroke spasticity of upper limb was identified,
a member of the treatment team invited them to take
part in the trial and provided the participant and the
caregiver with separate information leaflets on the
study. After 7 to 14 days a member of the study team
contacted the participant and the caregiver. Those who
agreed to participate in the study were invited to attend
a face to face appointment with a member of the study
team at the hospital. The study protocol is shown on
Fig. 2.
2.2 Study Protocol
Visit 1: During this visit participants and caregivers discussed
the study with the principal investigator, who obtained sepa-
rate informed consents from the participant and the caregiver.
The participants were screened according to the following
criteria. The inclusion criteria were 1) age 18 and above; 2)
stroke at least six months previously and 3) spasticity at elbow
flexor muscles of grade 2 or more on the Modified Ashworth
Scale (MAS). The exclusion criteria were 1) cognitive impair-
ment that would interfere with their ability to comply with the
experimental protocol or provide an informed consent; 2) der-
matological, rheumatologic or orthopedic conditions of the
affected arm interfering with movement of the elbow; 3)
Visit-1
• Informed consent,Eligibility criteria,physical examinaon
• Seven day spascity NRS daily diary
Visit-2
( Week-0)
• Baseline evaluaon of outcome meassures
• Randomisaon
• Intervenon started Group-1 TENS, Group-2 SBS
Visit-2
Week-2
• Home visit for electrode change and safety check
Visit-3
Week-4
•Return of the smulator






• Assessment of outcome meassure
• Commencement of Intervenon-2 ( Group-1 SBS and Group-2 
TENS)
Week 8
• Home visit for electrode change and safety check
Visit-5
Week-10
• Return of the smulator
• Assessment of outcome meassures and adverse events
• Paent percepon interview
Fig. 2 Study protocol
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pre-existing severe systemic disorders such as cardiovascular
disease, active cancer or renal disease, end stage pulmonary or
cardiovascular disease, psychiatric disorders including severe
alcohol or drug abuse and depression; 4) inability to perform
the baseline assessments; 5) severe tactile hypersensitivity; 6)
participation in other, spasticity related studies; 7) within
12 weeks of receiving Botulinum toxin injections; 8) poorly
controlled epilepsy; 9) pacemaker or any other implanted de-
vices, 10) inability of the caregiver to deliver the intervention
and 11) pregnancy.
The participants and caregivers were trained to record the
severity of spasticity in a paper diary daily between 6 pm and
9 pmon aNumerical Rating Scale (NRS) ranging from 0 to 10; 0
-no spasticity, 10 -worst spasticity one can imagine [21]. The
participants were asked to complete the NRS diary for 7 days
immediately prior to their randomization visit at the clinical re-
search facility.
Visit 2: The participants were randomly allocated to either
group-1 or group-2 using an online randomization website;
www.randomization.com. Initially the baseline outcome
measures were carried out by the assessor (who was blinded to
the allocation). Another researcher then setup the device for the
participant and demonstrated the use of the device. For their first
intervention participants in group-1 received TENS and those in
group-2 received SBS. The TENS or SBS were setup over the
extensor aspect of the affected upper arm and stimulation was
done for 60 min. The initial intervention was done at the Clinical
Research Facility within the Royal Hallamshire Hospital,
Sheffield, United Kingdom. The strength of stimulation was set
just below the motor threshold or the maximum tolerable stimu-
lation whichever was lower. The researcher checked for any
adverse effects after the intervention. The participants and care-
givers were trained to apply the electrodes and deliver the inter-
vention at home for 60 min a day for the next four weeks. After
2 weeks each participant was visited at home by the researcher to
check for any adverse events, ensure they were correctly setting
up the intervention, and to replace the electrodes.
Visit 3: The participants and caregivers returned after four
weeks of intervention. The participant was assessed with out-
comemeasures and adverse events. The outcomemeasures were
carried out by an assessor who did not know about the type of
intervention received by the participants. No interventions were
performed for the next two weeks.
Visit 4: After the two week washout period, the participants
attended the clinical research facility for the setup of the second
intervention. This time participants in group-1 received SBS and
group −2 received TENS. Before the second intervention was
started the outcome measures were carried out by the assessor
who was blinded to the intervention. The intervention was then
setup by the other researcher and tested for 60 min, checking for
any adverse effects. The participants and caregivers were trained
to apply the electrodes and deliver the intervention at home for
60 min a day for the next four weeks. Two weeks into the
intervention period the researcher carried out another home visit
to check for any adverse events, ensure they were correctly set-
ting up the intervention, and to replace the electrodes.
Visit 5: The blinded researcher assessed the outcome mea-
sures and looked for any adverse event after the intervention.
2.3 Interventions
SBS: Participants and caregivers were issued our 64-independent
channel stimulator (ShefStim-SBS) with a 64-channel electrode
array contained in a custom made arm strap (Fig. 1). ShefStim-
SBS enables stimulation to be applied in complex spatial and
temporal patterns to be applied via an array of 64 electrodes.
The stimulation patterns used in this study were the same as in
our previous published hospital based study [20]. The partici-
pants with help from caregivers applied the electrode array over
the extensor aspect of the affected upper arm. An adhesive hy-
drogel sheet (ST GEL-high impedance grade SCBZAB-05 M,
Sekisui Plastics, Japan) with a resistivity of 1.3 kΩ*m and a
thickness of 0.5 mm was laid over the surface of the electrode
array to act as the interface between the electrodes and the skin.
In this study we used a custom-made arm strap for holding the
stimulating electrode array in place for ease of home use. At the
start of the first session, intensity of stimulation was increased
until a muscle movement was first observed. The intensity level
would then be set at 90% of this value, or themaximum tolerable
level; whichever was lower. Stimulation continued at this level
with the site moving around the array electrodes for 60 min [20].
On the 15th day, one of the researchers visited the participants at
home to check whether there were any issues and to change the
hydrogel sheet. Participants and caregivers returned to the
Clinical Research Facility at the end of the fourth week to return
equipment and had the outcome assessments done.
TENS: We used the stimulation techniques tested in the pre-
vious studies, including our trial [10–13, 20]. The participants,
with help from caregivers, applied the single channel TENS
surface electrodes over the extensor aspect of the affected upper
arm – following prior training, placement was intended to be
over the radial nerve in the radial groove. The intensity of stim-
ulation was set to 90% of the motor threshold and TENS was
applied for 60 min daily for four weeks.
2.4 Outcome Measures
The criteria for trial feasibility were: (1) 60% or more of eligible
participants being consented for the trial and (2) 85% of the
recruited participants completing the protocol. We also collected
data on adherence with the intervention, adherence with comple-
tion of daily diary recording ofNRS, attendance for the follow up
appointments, rate of completion of the outcome measures and
perception of the participants and caregivers about study. We
assessed adherence of treatment by using the TENS user record
program which showed time use for TENS. We defined good
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compliance as use of at least 23 h and notmore than the 28 h. The
compliance of recording diary was noted by manually counting
the NRS data entries recorded by participants in their daily dia-
ries.We considered 80% ormore days with legible diary entry as
good adherence.
The outcome measures tested were participant reported
NRS for spasticity, Action Research Arm Test (ARAT) [22],
Leeds Adult Spasticity Impact Scale (LASIS) [23], Modified
Ashworth Scale (MAS) for spasticity of elbow flexor muscles,
muscle strength in affected elbow flexion and extension using
Medical Research Council (MRC) grading and a question-
naire designed to capture participant’s perception towards ef-
ficacy and acceptability of treatment. [24]. We used the
Minimal Clinically Important Difference (MCID) established
in the literature for defining response. The participants who
had a reduction in NRS of at least 18% after four weeks of
intervention were considered as responders [21]. Participants
with an increase in ARAT of at least 4 in raw score were also
considered as responders [25]. Currently there are no reported
MCID for MRC grade, MAS or LASIS.
2.5 Analysis
Analyses of the data were performed by two authors who were
not involved in the data collection or delivery of intervention.
As it was a feasibility study we focused on feasibility issues
and sample size calculations. We calculated recruitment rate,
reason for non- participation, adherence with the protocol,
acceptability, participants’ perceptions about the devices and
adverse events. All statistical analyses were performed using
SPSS Statistics version 18.0 (SPSS, Inc., Chicago, IL, USA).
A p value<0.05 was considered to be statistically significant.
The sample size was calculated using nQuery Advisor version
5.0. It was based on a two group t-test for equal means to
conduct a three arm randomized control trial of SBS, TENS
and ‘usual care’ control, to have 90% power to demonstrate a
MCID reduction of 18% in NRS at the 1% significance level,
to allow for multiple testing [26, 27].
3 Results
We approached 21 potential participants with post stroke up-
per limb spasticity, of whom 16 consented to take part in the
study (76%). Of the five who chose not to participate; three
did not give any reason and one had previous allergic reaction
for the TENS stimulation electrode. We excluded one partic-
ipant after screening as the participant had elbow flexor spas-
ticity of less than grade 2 onMAS. The consort diagram of the
study is shown on Fig. 3. One of the recruited participants
dropped out after randomization before starting the first inter-
vention. This participant was excluded from analysis. Overall
15 participants completed the study (94%), seven of whom
(47%) were men, and the age ranged from 28.8 to 70.5 years
(54.5 + 12.4 years). One of the participants was of Afro-
Caribbean ethic origin. All others were Caucasians. Five had
right-sided stroke and ten had left-sided stroke. All 16 partic-
ipants had spasicity of elbow flexor muscles of MAS of 2 or
more.
Ten participants (67%) showed good adherence with the
intervention and 11 (73%) showed good adherence in record-
ing NRS daily during the intervention period. All tolerated the
interventions well. There were four adverse events reported by
three participants. The adverse events were: 1) vasovagal syn-
cope during TENS period 2) headache and tingling feeling
down left arm in washout period 3) seizure at 18 h after the
application of SBS 4) nausea within TENS period. None of
the adverse events occurred while using TENS or SBS.
The MAS of the elbow reduced by at least 1 grade in five
participants after SBS and in three participants after TENS.
For the ARAT, a Minimal Clinically Important Difference
(MCID) of four points increase was seen in five participants
following TENS, and in four following SBS. AMCID of 18%
decrease in NRS was reported by eight participants after
TENS and in three after SBS. The LASIS score improved in
12 participants after TENS and in seven after SBS.
Fourteen participants (93%) completed the Participants’
Perception Questionnaire (Table 1), which sought feedback
on their experiences in using the two stimulation technologies
and in completing the outcome measures. Eight participants
preferred TENS while six preferred SBS. The most common
reasons behind participant’s choice of preference were ease of
administration (8), nature of the sensation (8) and perceived
effectiveness of the treatment (8). Eight participants offered
suggestions to improve the design of future studies, which
included aiding electrode placement for TENS (1), improving
SBS usability (4), such as facilitating single handed applica-
tion and the addition of a timer function. Other comments
included requests for a future study to include the shoulder,
and, a longer duration for each intervention period. Despite
the earlier SBS usability suggestions, one respondent
commented that they found SBS more convenient to use than
TENS and one noticed improvements in hand function fol-
lowing SBS.
Two participants did not agree that the ARAT was an ap-
propriate outcome measure, commenting that it was too diffi-
cult to complete or it led to frustration for their level of arm
function. Twelve of the 14 respondents would be prepared to
participate in a follow-up study (Table 2).
The sample size calculation for a two group t-test for
equal means showed that to conduct a three arm ran-
domized control trial of SBS, TENS and ‘usual care’
control, we would need 68 subjects per group (total
204 participants) to have 90% power to demonstrate a
MCID reduction of 18% in NRS at the 1% significance
level to allow for multiple testing [26, 27].
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4 Discussion
This study demonstrated that it is feasible to conduct a trial of
electrical sensory stimulation in the community with caregivers
assisting in the delivery of the intervention. The recruitment and
retention rates in this study are similar to recruitment and reten-
tion rates of participants in other randomized controlled trials
done in UK [28].
One of the difficulties in clinical trials with electrical stim-
ulation is delivery of the interventions in the community. The
interventions could take weeks and it is not practical for par-
ticipants to visit research facilities regularly for the
intervention. It is also not cost effective or practical for re-
search therapists to do home visits to deliver such interven-
tions. Our results showed that it is possible to train participants
and caregivers to deliver electrical stimulation for treating
elbow spasticity at home. Around two thirds (67%) showed
good adherence with the protocol. This is similar to the rate of
adherence of stroke survivors with home exercises program
(65%) and adherence across all types of medications (69%)
[29, 30] and better than the 50% adherence reported for oral
anti-spasticity medications. Future studies using electrical
stimulation at home should include an objective measure of
adherence such as an inbuilt user record within devices. We
Fig. 3 CONSORT flow diagram showing number of participants through each stage of the randomized crossover trial
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Table 1 Outcomes before and after interventions
TENS SBS
pre-intervention post-intervention p value pre-intervention post-intervention p value
Spasticity NRS 5 (4,6) 4 (4,6) 0.072 * 5 (5,6.5) 6 (4,7) 0.748 *
ARAT 28 (3,39) 28 (1,46) 0.102 * 36 (4,45) 33 (3,50) 0.504 *
LASIS 1.2 + 0.2 0.9 + 0.2 0.010† 1.2 + 0.2 1.2 + 0.2 0.915†
MAS 1.5 (1.5,2.0) 1.5 (1.5,2.0) 1.000 * 2.0 (1.5,2.0) 1.5 (1.0,2.0) 0.131 *
MRC grade (Elbow extension) 3 (2,4) 3 (2,4) 0.655 * 3 (2,4) 3 (2,4) 1.000 *
MRC grade (Elbow Flexion) 3 (2,4) 3 (3,4) 0.257 * 4 (2,4) 3 (2,4) 0.414 *
*Wilcoxon signed ranks test (value is median, Q1, Q3)
† paired t-test (value is mean + SEM)
Abbreviations: NRS =Numeric Rating Scale, ARAT =Action Research Arm Test, LASIS = Leeds Adult Spasticity Impact Scale, MAS =Modified
Ashworth Scale, MRC=Medical Research Council





1. Is the ARAT an appropriate test to assess the functioning of your arm? 12 2 – 1. Because of no hand function on right side due to tone,
cannot complete test.
2. It’s far too hard. Frustrating for the stage I am at.
2. Is the Leeds Spasticity Impact Scale an appropriate questionnaire to
assess the spasticity of your arm?
14 – –
4. Is TENS an appropriate treatment for you? 12 1 1
5. Is SBS an appropriate treatment for you? 11 2 1
`6. Do you have any preferences between TENS and SBS?
- 8 participants choose TENS
- 6 participants choose SBS
14 – –
What are the reasons behind your choice?
- Effectiveness of the treatment 8 3 3 1. Familiar
2. TENS-occasionally noticed ongoing tingling of forearm
after use for an hour but not uncomfortable
- Nature of the sensation 8 4 3
- Ease of administration 8 5 1
- Side effects - 11 3
- Others 2 3 9
7. Do you have any concerns about this study? 2 11 1 1. Not specified
2. Number of visits and home visit acceptable
8. Will you consider participating in future research using TENS or SBS? 12 – 2
9. Have you any suggestions to improve the design of future studies using
TENS and SBS?
8 2 4 1. Design of application of SBS for ease of use
2. Ease of use for SBS, number of visits to be reduced for
convenience
3. Having the times on SBS would help as it’s easy to forget
to set the separate times
4. To make easier to apply on own (need 2 hands to apply)
5. Small cuff
6. SBS hard to get on by self. Better if it was something you
could pull on
7. We should look at shoulder. This study looked at elbow.
8. Better way of marking arm for correct position of pads
10. Any other comments? 4 – 10 1. Further study with longer duration of each intervention
period.
2. Enjoyed taking part. Feel left arm is not as tight. Increased
use of Lt. arm in activity of daily living.
3. SBS more convenient to use.
4. SBS helped with moving left fingers on their own.
Abbreviations: N/A = not answer
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plan to refine the ShefStim-SBS device further to include con-
current usage monitoring.
Participant reported outcome measures are important in
studies of post stroke spasticity. We used NRS and LASIS.
LASIS is recommended by the Royal College of Physicians
UK as an outcome measure for post stroke upper limb spas-
ticity [24]. Further research is required to establish MCID on
LASIS. Recording LASIS was successful in all our partici-
pants, who also felt that this is an appropriate measure to
study. During treatment with TENS participants reported im-
provement on LASIS. Our study had only 16 participants and
used multiple outcome measures. In view of these limitations
further research is required to establish whether TENS im-
prove LASIS in people with post stroke upper limb spasticity.
The participant reported NRS is a well-accepted outcome
measure for spasticity with a moderate to high level of corre-
lation with other clinician rated instruments used to assess
spasticity [31]. This measure was used successfully to get
FDA approval for Nabiximols for treatment of spasticity in
multiple sclerosis [32]. One of the issues is that participants or
caregivers need to record the NRS daily. This could be a
problem for studies where intervention could last several
weeks. In our study we noted that 11 out of 15 participants/
caregivers recorded NRS for more than 80% of the days, using
a paper diary. An electronic diary with automated daily re-
minders could improve the capture of the NRS and we plan
to deliver and investigate this in a follow-up study.
This study demonstrated that sensory electrical stimulation
delivered by caregivers in the community is a safe and well
tolerated by participants with post stroke upper limb spastici-
ty. Six participants preferred SBS and eight preferred TENS.
The SBS was delivered using a prototype device which was
more cumbersome to don and doff and difficult to operate.
Improvements in design, especially ease of application of
the wearable arm sleeve with integrated electrode array and
incorporation of a timer are expected to further improve the
acceptability of the SBS and this work is planned.
4.1 Limitations
Our data did not show any conslusive evidence that multi-
channel stimulation was superior to single channel stimulation
for post stroke upper limb spasticity. As a feasibility trial, this
study was not designed to evaluate the efficacy of the inter-
ventions. Hence these data should not be used to justify or
refute the use of electrical sensory stimulation as a treatment
for post stroke upper limb spasticity. The study recruited only
participants with spasticity six months ormore after stroke and
who had a caregiver able to administer the intervention. Hence
the results are not generalizable to all participants with post
stroke spasticity and in fact may have focused on participants
with less resolvable spasticity. The World Health
Organization’s ‘International Classification of Functioning,
Disability and Health’ (ICF) provides a framework that allows
the systematic categorization of clinical observations [33].
The areas include impairment, activity limitation, restriction
in participation and quality of life. We measured impairment
using MRC grading of muscle power and muscle tone using
MAS. The ARAT and LASIS reflect limitation of activities
involving upper limb function. We did not record measures of
social participation or quality of life (QoL) in this study. A
future study planned will include the EQ-5D, an internation-
ally recognized and validated QoL tool, or potentially the
spasticity-related QoL tool, the SQoL-6D [34], which is still
in final validation.
Commercially available TENS devices are regulated for
managing pain and not as a spasticity therapy, so such usage
is restricted to a research setting. The use of separate single-
channel TENS as a comparator to SBS was a further study
limitation. While it enabled the stimulation modality to be
investigated and contrasted scientifically, it resulted in some
of the potential advantages of the ShefStim-SBS being artifi-
cially restricted, in that its 64 stimulating channels could have
been distributed across several joints. Single channel TENS
can only stimulate one joint, and thus to contrast like-with-
like, only one joint, the elbow, could be treated in this study.
Furthermore, the use of two different stimulators meant that
the participants were aware of the differences in the interven-
tions. A future study of a refined ShefStim-SBS will offer two
potential benefits.
1. Its 64 independent channel programmability, together
with new electrode designs, will permit the same
ShefStim-SBS device to simulate and deliver single chan-
nel TENS thus providing device blinding for the TENS
intervention arm.
2. In addition, it would be possible to utilize the ShefStim-
SBS stimulating channels across several joints of the up-
per limb to maximize therapeutic effect.
Work is underway to develop and test new preparation
techniques to improve and prolong hydrogel performance to
reduce researcher visits and participant /carer burden.
5 Conclusions
Multichannel sensory electrical stimulation of the upper arm
using the unique 64-independent channel ShefStim-SBS is
safe and well tolerated by participants with post stroke spas-
ticity. It is feasible to train caregivers to deliver sensory elec-
trical stimulation at home, and conduct a randomized con-
trolled trial to test single and multi-channel sensory electrical
stimulation in a domiciliary setting. Our suggestions for this
follow-up trial include:
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(1) a randomized control design
(2) 204 participants divided into three arms (‘usual care’
control, TENS and SBS)
(3) use of electronic reminders for delivery of intervention
and recording NRS
(4) inclusion of measures of quality of life and social
participation
(5) utilizing a refined ShefStim-SBS device to provide
blinded TENS and SBS intervention arms and
(6) investigating the utility of ShefStim-SBS concurrent
multi-joint sensory stimulation for upper limb spasticity
therapy using different electrode array configurations.
Further studies on sensory electrical stimulation in acute
and subacute phases of stroke are also warranted and
may prove more receptive to spasticity improvement.
The research should also explore the option of combining
sensory electrical stimulation with other interventions to im-
prove upper limb function such as motor electrical stimulation
(which could be achieved with ShefStim-SBS) or Constraint
Induced Movement Therapy (CIMT) [35].
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